Planetary health investing and biotech investing are more alike than most practitioners in either camp realize. Yet the two ecosystems have largely evolved in parallel, developing their own governance norms, financing conventions, and public-market strategies. That separation is a missed opportunity. 

Repatriating the American drug supply is key not just to averting shortages but to restoring and preserving the integrity of generic drugs in America.